Advertisement
Screener

LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3

LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3

LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 of $3.88 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 · last filed 2019-02-28

  • LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for the quarter ending 2015-12-31 was -$765.00K.
  • LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for the quarter ending 2015-09-30 was $0.00.
  • LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2018 was $3.88M, a 1838.50% increase from fiscal 2017.
  • LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2017 was $200.00K, a 33.33% decline from fiscal 2016.
  • LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2016 was $300.00K, a 93.73% decline from fiscal 2015.
  • LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 for fiscal 2015 was $4.78M.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 3 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 6 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 9 monthFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 12 month
2018-12-31$3.88M
10-K · filed 2019-02-28
2017-12-31$200.00K
10-K · filed 2018-03-01
2016-12-31$300.00K
10-K · filed 2017-02-28
2015-12-31-$765.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-14
-$765.00K
derived: sum of 2 quarters · filed 2016-11-14
$4.78M
10-K · filed 2016-11-14
2015-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$5.55M
10-Q · filed 2015-11-09
2015-06-30$5.55M
10-Q · filed 2015-08-05